Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3430 | Proxalutamide Wiki | 0.71 |
drug1392 | Dutasteride Wiki | 0.71 |
drug3391 | Problem-solving and relationship improvement intervention. Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D011470 | Prostatic Hyperplasia NIH | 0.71 |
D000505 | Alopecia NIH | 0.50 |
D001997 | Bronchopulmonary Dysplasia NIH | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0008711 | Benign prostatic hyperplasia HPO | 0.71 |
HP:0002293 | Alopecia of scalp HPO | 0.50 |
Navigate: Correlations HPO
There are 2 clinical trials
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
Description: Percentage of subjects hospitalized due to COVID-19
Measure: COVID-19 hospitalization Time: 30 daysDescription: COVID Ordinal Scale defined as: Death Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation) Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)
Measure: COVID-19 Ordinal Outcomes Scale Time: 30 daysDescription: Symptoms severity of COVID-19 using Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm
Measure: Symptoms severity of COVID-19 Time: 30 daysThe purpose of this study is to determine if an investigational drug, AT-100, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature at 36 weeks Postmenstrual Age (PMA), as compared to babies born premature who receive standard neonatal care alone.
Description: Dose escalation of AT-100 up to the maximum feasible dose in order to assess safety and tolerability
Measure: Phase 1b: Determining the highest-tolerated & safety-tested AT-100 dose Time: From time of initial AT-100 dosing until end of the dosing period, up to 7 daysDescription: Days on mechanical ventilation.
Measure: Phase 2: Reduction in time on mechanical ventilation Time: From birth to 36 Weeks Postmenstrual Age (PMA)Description: Incidence of BPD or death.
Measure: BPD or death Time: At 36 Weeks PMADescription: Days on mechanical ventilation.
Measure: Long term reduction in time on mechanical ventilation Time: From birth to 1 year Corrected Age (CA)Description: Days on respiratory oxygen support.
Measure: Long term reduction in time on respiratory support Time: From birth to 1 year Corrected Age (CA)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports